Chronic TNF-α neutralization does not improve insulin resistance or endothelial function in "healthy" men with metabolic syndrome

Molecular Medicine

Volumn 17, Issue 3-4, 2011, Pages 189-193

  Wascher, Thomas C ^a,c   Lindeman, Jan H N ^b   Sourij, Harald ^a   Kooistra, Teake ^d   Pacini, Giovanni ^e   Roden, Michael ^c,f  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c First Dept of Med/Medical Oncology   (Austria)

^d TNO   (Netherlands)

^e CNR   (Italy)

^f HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; FIBRINOGEN; INFLIXIMAB; PLACEBO; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; ENDOTHELIAL DYSFUNCTION; HOMEOSTASIS; HUMAN; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRAVENOUS GLUCOSE TOLERANCE TEST; MALE; METABOLIC SYNDROME X; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; VASODILATATION;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; C-REACTIVE PROTEIN; ENDOTHELIUM, VASCULAR; FIBRINOGEN; GLUCOSE TOLERANCE TEST; HUMANS; INFUSIONS, INTRAVENOUS; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; OBESITY; PROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79952856377     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2010.00221     Document Type: Article

References (32)

1. Pradhan A. (2007) Obesity, metabolic syndrome, and type 2 diabetes: inflammatory basis of glucose metabolic disorders. Nutr. Rev. 65:S152-6.
2. Bays HE, et al. (2008) Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity. Expert Rev. Cardiovasc. Ther. 6:343-368.
3. Hotamisligil GS. (1999) The role of TNFalpha and TNF receptors in obesity and insulin resistance. J. Intern. Med. 245:621-5.
4. Dandona P, et al. (1998) Tumor necrosis factoralpha in sera of obese patients: fall with weight loss. J. Clin. Endocrinol. Metab. 83:2907-2910.
5. Zhang S, Kim KH. (1995) TNF-alpha inhibits glucose- induced insulin secretion in a pancreatic beta-cell line (INS-1). FEBS Lett. 377:237-239.
6. Cawthorn WP, Sethi JK. (2008) TNF-alpha and adipocyte biology. FEBS Lett. 582:117-131.
7. Araujo EP, et al. (2007) Infliximab restores glucose homeostasis in an animal model of dietinduced obesity and diabetes. Endocrinology. 148:5991-5997.
8. Gonzalez-Gay MA, et al. (2006) Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis. Clin. Exp. Rheumatol. 24:83-86.
9. Kiortsis DN, Mavridis AK, Vasakos S, Nikas SN, Drosos AA. (2005) Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis. Ann. Rheum. Dis. 64:765-766.
10. Ofei F, Hurel S, Newkirk J, Sopwith M, Taylor R. (1996) Effects of an engineered human anti-TNFalpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes. 45:881-885.
11. Dominguez H, et al. (2005) Metabolic and vascular effects of tumor necrosis factor-alpha blockade with etanercept in obese patients with type 2 diabetes. J. Vasc. Res. 42:517-525.
12. Paquot N, Castillo MJ, Lefèbvre PJ, Scheen AJ. (2000) No increased insulin sensitivity after a single intravenous administration of a recombinant human tumor necrosis factor receptor: Fc fusion protein in obese insulin-resistant patients. J. Clin. Endocrinol. Metab. 85:1316-1319.
13. Bernstein LE, Berry J, Kim S, Canavan B, Grinspoon SK. (2006) Effects of etanercept in patients with the metabolic syndrome. Arch. Intern. Med. 166:902-8.
14. von Bibra H, St John Sutton M. (2010) Diastolic dysfunction in diabetes and the metabolic syndrome: promising potential for diagnosis and prognosis. Diabetologia. 53:1033-1045.
15. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol on Adults. (2001) Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 285:2486-2497.
16. Matthews DR, et al. (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 28:412-419.
17. Pacini G, et al. (1998) Insulin sensitivity and glucose effectiveness: minimal model analysis of regular and insulin-modified FSIGT. Am. J. Physiol. 274:E592-9.
18. Hukshorn CJ, et al. (2004) Leptin and the proinflammatory state associated with human obesity. J. Clin. Endocrinol. Metab. 89:1773-1778.
19. Stuehlinger MC, et al. (2003) Endothelial dysfunction induced by hyperhomocyst(e)inemia: role of asymmetric dimethylarginine. Circulation. 26:933-938.
20. Hotamisligil GS, Shargill NS, Spiegelman BM. (1993) Adipose expression of tumor necrosis factor- alpha: direct role in obesity-linked insulin resistance. Science. 259:87-91.
21. Hotamisligil GS. (1999) Mechanisms of TNFalpha- induced insulin resistance. Exp. Clin. Endocrinol. Diabetes. 107:119-25.
22. Liang H, et al. (2008) Blockade of tumor necrosis factor (TNF) receptor type 1-mediated TNF- alpha signaling protected Wistar rats from dietinduced obesity and insulin resistance. Endocrinology. 149:2943-2951.
23. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. (1997) Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature. 389:610-614.
24. Ishikawa K, et al. (2006) Subcutaneous fat modulates insulin sensitivity in mice by regulating TNF-alpha expression in visceral fat. Horm. Metab. Res. 38:631-638.
25. Schreyer SA, Chua SC Jr, LeBoeuf RC. (1998) Obesity and diabetes in TNF-alpha receptordeficient mice. J. Clin. Invest. 102:402-411.
26. Pamir N, McMillen TS, Kaiyala KJ, Schwartz MW, LeBoeuf RC. (2009) Receptors for tumor necrosis factor-alpha play a protective role against obesity and alter adipose tissue macrophage status. Endocrinology. 150:4124-4134.
27. Mohamed-Ali V, et al. (1997) Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J. Clin. Endocrinol. Metab. 82:4196-4200.
28. Lindeman JH, et al. (2007) Human visceral adipose tissue and the plasminogen activator inhibitor type 1. Int. J. Obes. (Lond). 31:1671-1679.
29. Di Rocco P, Manco M, Rosa G, Greco AV, Mingrone G. (2004) Lowered tumor necrosis factor receptors, but not increased insulin sensitivity, with infliximab. Obes Res. 12:734-739.
30. Scallon B, et al. (2002) Binding and functional comparisons of two types of tumor necrosis factor antagonists. J. Pharmacol. Exp. Ther. 301:418-426.
31. Arora T, et al. (2009) Differences in binding and effector functions between classes of TNF antagonists. Cytokine. 45:124-131.
32. Hummasti S, Hotamisligil GS. (2010) Endoplasmic reticulum stress and inflammation in obesity and diabetes. Circ. Res. 107:579-591